ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
release to report its preliminary unaudited financial results for
the three months ended March 31, 2017. The press release is
furnished herewith as Exhibit 99.1.
Exhibit 99.1, is furnished to Item 2.02 and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, or otherwise subject to the liability of
that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except
as shall be expressly set forth by specific reference in such a
filing.
|
Exhibit
Number
|
Description
|
|
99.1
|
Press Release dated May 4, 2017.
|
About ENDOLOGIX, INC. (NASDAQ:ELGX)
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths. ENDOLOGIX, INC. (NASDAQ:ELGX) Recent Trading Information
ENDOLOGIX, INC. (NASDAQ:ELGX) closed its last trading session down -0.04 at 7.34 with 984,928 shares trading hands.
